Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7749748 | 1.00 | CYP2C9 (0.57) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| Hydrochloric Acid SCHEMBL8368672 | 0.98 | CYP2C9 (0.56) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| Hydrochloric Acid SCHEMBL8368674 | 0.98 | CYP2C9 (0.56) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| Trifluoroacetic Acid SCHEMBL8763902 | 0.90 | CYP2C9 (0.49) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL28046500 | 0.87 | CYP2C9 (0.57) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL28046501 | 0.87 | CYP2C9 (0.57) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL25724298 | 0.85 | CYP2C9 (0.62) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL11940463 | 0.85 | CYP2C9 (0.58) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL6501861 | 0.83 | CYP2C9 (0.51) | CYP2C9ALDH1A1TSHRL3MBTL1TAS1R3 | |
| SCHEMBL1158063 | 0.83 | LMNA (0.51) | ALDH1A1USP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0783305-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| EP-0783518-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0783305-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | CYP2C9 2604/4885ALDH1A1 1940/4885TSHR 2801/4885 |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | CYP2C9 2604/4885ALDH1A1 1940/4885TSHR 2801/4885 |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | CYP2C9 2604/4885ALDH1A1 1940/4885TSHR 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.